Nicola Groth named Osivax CMO

Osivax, a French biopharma developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, has named Nicola Groth its new chief medical officer (CMO).

She brings more than 25 years of experience in vaccine development and has considerable expertise in influenza vaccines, from early-stage clinical development to approval and post-marketing commitments.

"Nicola’s experience in managing late-stage clinical trials and building registration packages for influenza vaccines will be crucial"